top of page

HoneyNaps successfully participated in the "Sleep 2022" exhibition held in the United States

Reported by Asia Economy / Jun 10, 2022



The "SLEEP 2022" medical conference, organized by the American Academy of Sleep Medicine (AASM) and Associated Professional Sleep Societies, took place in Charlotte, North Carolina, USA from June 4th to 8th, 2022. It is the largest sleep medicine conference in the world. The event featured over 100 sessions, more than 700 research papers, and the participation of over 130 global sleep specialty companies in the exhibition.


HoneyNaps, as the first Korean company, has set up a booth at the conference and presented their research paper on sleep biomarker analysis algorithms. Under the theme of "Sleep Expert toward 4P Medicine," they exhibit AI diagnostics and digital therapeutic solutions. They demonstrated several notable solutions such as ▲ SOMNUM, an AI-based software for diagnosing sleep disorders, ▲ SOMNUM Scanning, a contact-free sleep analysis and coaching solution, and ▲ SOMNUM Medella, a digital therapeutic solution for insomnia.



During the exhibition, HoneyNaps received a high level of interest from approximately 500 global company representatives, including sleep specialists from Massachusetts General Hospital (MGH), Stanford University School of Medicine, University of Pittsburgh Medical Center, and Cleveland Clinic. Additionally, representatives from companies such as ResMed, Philips, Compumedics, Onera Health, and Inspire visited HoneyNaps' booth. This demonstrates the significant attention and recognition that the Korean company garnered during the event.


A representative from HoneyNaps stated, "There was a significant interest in our SOMNUM XAI software, which automatically interprets polysomnography (PSG) results and provides explanations for diagnostic outcomes. We have also made progress in advancing contract negotiations with several multinational companies. Additionally, we have secured clinical partnerships with renowned academic hospitals in the United States for our second-generation digital therapeutic solution, SOMNUM Medella. We plan to accelerate the outcomes achieved at Sleep 2022 through our U.S. subsidiary later this year."

Komentarze


bottom of page